Company Template

ABOUT IPSEN

Improving lives and health outcomes

At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 5,000 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers.

PURPOSE

For patients & society

Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term.

VISION

Quality of life of patients

Ipsen’s vision is to be a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in three key therapeutic areas: oncology, rare disease and neuroscience.

MISSION

Accelerate rare disease diagnosis

There are 7,000 rare diseases affecting 300 million people worldwide. 75% of patients are children. 1 in 2 patients does not have an accurate diagnosis. A quarter of patients wait 4 years to get a diagnosis. Our program brings together world experts to improve this dire situation.

Our strategy

Under the overarching theme of Focus. Together. For patients & society, Ipsen is focusing on four strategic priorities to accelerate our innovation and drive positive impact for patients, employees, shareholders and society—a strategy for the short and long term.

We are working to maximize the value of our core products. Our objective is to take patient-centricity to the next level by truly impacting medical care and patient outcomes in our therapeutic areas, notably by building a deep understanding of the patient journey. Patient insights are essential to challenge the status quo, while collaboration with healthcare systems can bring about advancements for patients around the world.

We changed how we screen companies and compounds, so we can make decisions faster and focus on the ones we want to push forward.

Chief Executive Ofiicer

Growth

We want to broaden and deepen our expertise as well as fully leverage the collective intelligence of the company. We are accelerating our efforts to truly embrace diversity in all our facets and make Ipsen a more inclusive organization.

2021 Sales

Neuroscience is deeply rooted within Ipsen as a key strategic driver for our business. Through our strategy in external innovation, we are actively expanding our pipeline into neurodegenerative disorders .

€2869.9 M

Total sales 2021
+12.3 % YOY

€2153.5 M

2021 Oncology sales
+10.8 % YOY

35.2%

Record core
operating margin

€440.7 M

2021 Rare disease sales
-10.4% YOY

Research & Development

€2869.9 M

Total sales 2021
+12.3 % YOY

€2153.5 M

2021 Oncology sales
+10.8 % YOY

35.2%

Record core
operating margin

€440.7 M

2021 Rare disease sales
-10.4% YOY

CSR Initiatives

€2869.9 M

Total sales 2021
+12.3 % YOY

€2153.5 M

2021 Oncology sales
+10.8 % YOY

35.2%

Record core
operating margin

€440.7 M

2021 Rare disease sales
-10.4% YOY

Global presence

We are an international group, with Ipsen products registered in over 115 countries. We expanded our footprint in 2021 to include Japan and Dubai. Today, our revenues are distributed across North America, the EU5 (France, Germany, Italy, Spain and the United Kingdom), other European countries and the rest of the world.

History

Revisit our rich history and accomplishments for over 94 years

Jul 2022

Ipsen announces the closing of its agreement to divest its CHC business to Mayoly Splinder

Jul 2021

Ipsen strengthens its pre-clinical oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc…

May – Dec 2020

Ipsen announces new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients

FONDATION IPSEN

Scientific community

For several decades, Fondation Ipsen has been working to improve the public’s living conditions by disseminating scientific knowledge to the general public and promoting exchanges.

Know more